Evidence map›Paper›PMID 41459844›Full record

SynthesisAsian Pacific journal of cancer prevention : APJCP2025

Precision Medicine and Artificial Intelligence in Next-Generation Cancer Surgery: A Comprehensive Analysis of Clinical Applications, Therapeutic Outcomes, and Implementation Strategies.

Alireza Negahi, Mehdi Khosravi-Mashizi, Hossein Najdsepas, Hossein Negahban, Seyede Arefe Mousavi-Beni, Reza Shahrokhi Damavand, Amirhosein Naseri, Fatemeh Jayervand, Amirhossein Shahbazi, Amirhossein Rahmani and 1 more

Abstract readSystematic Review
In one paragraph

Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alireza NegahiBreast Health & Cancer Research Center, Iran University of Medical Sciences, Tehran, Iran.
Mehdi Khosravi-MashiziBreast Health & Cancer Research Center, Iran University of Medical Sciences, Tehran, Iran.
Hossein NajdsepasBreast Health & Cancer Research Center, Iran University of Medical Sciences, Tehran, Iran.
Hossein NegahbanBreast Health & Cancer Research Center, Iran University of Medical Sciences, Tehran, Iran.
Seyede Arefe Mousavi-BeniAfshar Hospital Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Reza Shahrokhi DamavandUrology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Amirhosein NaseriDepartment of Colorectal Surgery, Imam Reza Hospital, AJA University of Medical Sciences, Tehran, Iran.
Fatemeh JayervandDepartment of Obstetrics and Gynecology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Amirhossein ShahbaziStudent Research Committee, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Amirhossein RahmaniDepartment of Plastic Surgery, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Hossein NeamatzadehHematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer surgery is undergoing transformative integration of precision medicine, artificial intelligence (AI), robotics, advanced imaging, and molecular technologies. These innovations promise enhanced surgical precision, improved patient outcomes, and personalized treatment approaches through data-driven decision-making.

methodsA comprehensive systematic literature review was conducted across PubMed, Embase, Cochrane Library, and Web of Science databases from January 2020 to November 2025. Studies were analyzed for clinical applications, therapeutic outcomes, cost-effectiveness, and implementation challenges. Primary endpoints included surgical accuracy, margin status, survival outcomes, complication rates, and technology adoption metrics.

resultsPrecision medicine utilizing genomic profiling and circulating tumor DNA demonstrated 94.9% sensitivity and 88.8% specificity in multi-cancer detection. The CIRCULATE-Japan GALAXY study showed ctDNA positivity during the molecular residual disease window predicted significantly inferior disease-free survival (HR 11.99; P < 0.0001) and overall survival (HR 9.68; P < 0.0001). AI-assisted surgical systems achieved area under the curve values of 0.76-0.85 in outcome prediction and reduced surgical complications by 25-30%. The da Vinci 5 robotic system demonstrated 43% reduction in tissue damage through force feedback technology. Meta-analysis of 15,137 patients showed robotic pancreatoduodenectomy reduced hospital stays and conversion rates compared to laparoscopy. Fluorescence-guided surgery achieved improved 5-year overall survival (80.6% vs. 66.7%, P = 0.018) in gastric cancer. Mass spectrometry techniques achieved 93.4-97.1% diagnostic accuracy. Perioperative immunotherapy in non-small cell lung cancer reduced recurrence risk by 43% (HR 0.57) and improved pathological complete response rates over 5-fold (RR 5.58). Nanotechnology-based delivery systems reduced cardiac toxicity (6% vs. 21%) while maintaining therapeutic efficacy.

conclusionsThe convergence of precision medicine, AI, robotics, and molecular technologies is revolutionizing cancer surgery toward personalized, data-driven interventions with substantial clinical outcome improvements. Implementation challenges including cost, standardization, and healthcare disparities require systematic addressing for widespread adoption.

Indexed as

Artificial IntelligenceNeoplasmsPrecision MedicineHumansArtificial intelligencecancer surgeryLiquid BiopsyPrecision medicinerobotic surgery

Identifiers

PMID41459844
PMCPMC13236084

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.